In senescent cells, FOXO4 sequesters p53 in the nucleus, preventing it from initiating the programmed cell death (apoptosis) that would normally eliminate the damaged cell
A systematic review in 2025 identified one qualifying clinical study: a retrospective analysis in which 7 of 12 subjects with chronic knee pain reported relief for over six months following intra-articular injection

Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
2021;384:9891002) a landmark result at the time of its publication
Diet and lifestyle factors associated with cognitive performance in college students